Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial

Abstract

BackgroundRotavirus vaccines are now globally recommended by the World Health Organization (WHO), but in early 2009 WHO’s Strategic Advisory Group of Experts on Immunization reviewed available data and concluded that there was no evidence for the efficacy or effectiveness of a two-dose schedule of the human rotavirus vaccine (HRV; Rotarix) given early at 6 and 10 wk of age. Additionally, the effectiveness of programmatic rotavirus vaccination, including possible indirect effects, has not been assessed in low-resource populations in Asia.Methods and findingsIn Bangladesh, we cluster-randomized (1:1) 142 villages of the Matlab Health and Demographic Surveillance System to include two doses of HRV with the standard infant vaccines at 6 and 10 wk of age or to provide standard infant vaccines without HRV. The study was initiated November 1, 2008, and surveillance was conducted concurrently at Matlab Diarrhoea Hospital and two community treatment centers to identify children less than 2 y of age presenting with acute rotavirus diarrhea (ARD) through March 31, 2011. Laboratory confirmation was made by enzyme immunoassay detection of rotavirus antigen in stool specimens. Overall effectiveness of the HRV vaccination program (primary objective) was measured by comparing the incidence rate of ARD among all children age-eligible for vaccination in villages where HRV was introduced to that among such children in villages where HRV was not introduced. Total effectiveness among vaccinees and indirect effectiveness were also evaluated. In all, 6,527 infants were age-eligible for vaccination in 71 HRV villages, and 5,791 in 71 non-HRV villages. In HRV villages, 4,808 (73.7%) infants received at least one dose of HRV. The incidence rate of ARD was 4.10 cases per 100 person-years in non-HRV villages compared to 2.8 per 100 person-years in HRV villages, indicating an overall effectiveness of 29.0% (95% CI, 11.3% to 43.1%). The total effectiveness of HRV against ARD among vaccinees was 41.4% (95% CI, 23.2% to 55.2%). The point estimate for total effectiveness was higher against ARD during the first year of life than during the second (45.2% versus 28.9%), but estimates for the second year of life lacked precision and did not reach statistical significance. Indirect effects were not detected. To check for bias in presentation to treatment facilities, we evaluated the effectiveness of HRV against acute diarrhea associated with enterotoxigenic Escherichia coli; it was 4.0% (95% CI, −46.5% to 37.1%), indicating that bias likely was not introduced. Thirteen serious adverse events were identified among recipients of HRV, but none were considered related to receipt of study vaccine. The main limitation of this study is that it was an open-label study with an observed-only control group (no placebo).ConclusionsThe two-dose HRV rotavirus vaccination program significantly reduced medically attended ARD in this low-resource population in Asia. Protection among vaccinees was similar to that in other low-resource settings. In low-resource populat...

Incidence of Acute Diarrhea-Associated Death among Children < 5 Years of Age in Bangladesh, 2010–12

“…Consequently, introducing rotavirus vaccine in Bangladesh could prevent acute diarrheal episodes and reduce the contribution of diarrhea in childhood deaths. Although the rotavirus vaccine is not as effective in Bangladesh as compared with the high-income countries, it still prevented 41% of illnesses 27 which could substantially reduce the burden of diarrhea in Bangladesh. Ascertaining cause of death and attributing a single cause of death among children is a conceptual over-simplification as comorbidity often occurs and many circumstances contribute to child deaths.…”

Effectiveness of monovalent rotavirus vaccine in the Philippines

“…Earlier results from high income countries of Asia in Hong Kong 7 and Japan 8 , where RVV are self-financed, revealed RVV effectiveness of 89% and 70%, respectively against diarrheal hospitalization. However, a cluster-randomized study conducted in Bangladesh, a low income country, revealed that the monovalent RVV effectiveness was 41.4% 9 .…”

Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial

“…29 The study on rotavirus vaccine 29 showed that only 68 (26%) of 258 of children who did not have increased rotavirus-specific IgA antibody-secreting cell levels at onset of vaccination developed significant IgA antibody-secreting cell responses to the rotavirus vaccine despite the same vaccine inducing protection in 45% of infants in similar populations in Bangladesh. 30 These results suggest that measuring circulating antibody-secreting cell or ALS responses is not optimal for assessment of mucosal immune responses to oral enteric vaccines in very young children. In this study, we show that secretory IgA anticolonisation factor antibody responses in faecal extracts were considerably more frequent in infants than were ALS IgA responses to the same antigens.…”